IQARUS spreads its wings with ExMed acquisition

MML backed IQARUS (www.iqarus.com) has accelerated its global growth strategy through the acquisition of Exmed, a leader in medical solutions in some of the most remote and challenging operating environments worldwide.

Exmed’s services include remote medical support, equipment and clinical education. These services are provided to prominent international government and humanitarian agencies as well as global energy companies and media organisations.

Tim Mitchell, CEO of IQARUS comments:

“Our ambition since launching IQARUS has been to rapidly grow into a global provider of health solutions in the world’s difficult and remote environments. The acquisition of Exmed is a major catalyst for our international expansion. The team are amongst the most highly regarded providers of healthcare in challenging locations. The calibre of international humanitarian and government customers that they serve and the level of trust that they command in the market is a testament to their skill and professionalism. We are proud that they will be joining IQARUS and will play a key role in our growth going forward.”

Robert Devonshire, MML, comments:

“This acquisition is a major step in IQARUS’s global ambitions. The team have made impressive progress in executing their international strategy and we look forward to continuing to support it.”

MML invested into IQARUS in October 2015 from its recently raised €438m Fund VI.

IQARUS was acquired as a platform from which to develop an international provider of remote healthcare solutions. Exmed is the second acquisition that MML has supported alongside significant investment in new IT for technology enabled medical solutions.

Read more about
Share this story
Share on linkedin
Share on twitter
Share on facebook
Related news
IQARUS continues its expansion with RSOH acquisition 
IQARUS acquires occupational hygiene expertise
MML takes flight with IQARUS

MML investor portal logins

For investors in MML Fund VI, MML Ireland I & MML Ireland II

For investors in MML Fund VII